The problem with NSAIDs: What data to believe?

Current Pain and Headache Reports

Volumn 11, Issue 6, 2007, Pages 423-427

  McKellar, Gayle ^a   Madhok, Rajan ^b   Singh, Gurkirpal ^b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTAGLANDIN DERIVATIVE; PROTON PUMP INHIBITOR; ROFECOXIB; VALDECOXIB;

ADENOMATOUS POLYP; ANALGESIC ACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENZYME INHIBITION; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL DISEASES; HUMANS;

EID: 36849040409     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-007-0228-y     Document Type: Review

References (35)

1. Lawrence RC, Helmick CG, Arnett FC, et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778-799.
2. Singh G: Treatment options for osteoarthritis. Surg Technol Int 2003, 11:287-292
3. Krumholz HM, Ross JS, Presler AH, Egilman DS: What have we learnt from Vioxx? Br Med J 2007, 334:120-123.
4. US food and Drug Administration: Public health advisory: non-steroidal anti-inflammatory drug products (NSAIDs). December 23, 2004. Available at http://www.fda.gov/cder/drug/advisory/nsaids.htm. Accessed July 2006.
5. Brune K, Zeilhofer HU: Antipyretic analgesics: basic aspects. In Textbook of Pain, edn 5. Edited by McMahon SB, Koltzenburg M. Philadelphia: Elsevier; 2005:459-470.
6. Vane J, Botting R: Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J 1987, 1:89-96.
7. Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA: Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006, 98:266-274.
8. Singh G, Wu O, Langhorne P, Madhok R: Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res Ther 2006, 8:R153
9. McGettigan P, Henry D: Cardiovascular risk of inhibition of cyclo-oxygenase. JAMA 2006, 296:1633-1644.
10. Kearney PM, Baignent C, Godwin J, et al.: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006, 332:1302-1308.
11. Cannon CP, Curtis SP, FitzGerald GA, et al.: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofcnac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006, 368:1771-1781.
12. Gislason GH, Jacobsen S, Rasmussen JN, et al.: Risk of death or reinfarction associated with the use of selective cyclooygenase-2 inhibitors and non-selective non-steroidal anti-inflammatory drugs after acute myocardial infarction. Circulation 2006, 113:2906-2913.
13. Aisen PS, Schafer K, Grundman M et al.: NSAIDS and hypertension. Arch Intern Med 2003, 163:1115.
14. Johnson AG, Nguyen TV, Day RO: Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289-300.
15. Singh G, Miller JD, Huse DM, et al.: Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 2003, 30:714-719.
16. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomised to doxazosin vs chlorthalidone. JAMA 2000, 283:1967-1975.
17. Huerta C, Varas-Lorenzo C, Castellsague J, Garcia Rodriguez LA: Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population. Heart 2006, 92:1610-1615.
18. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs. N Engl J Med 1999, 340:1888-1899.
19. Singh G, Ramey DR, Morfeld D, et al.: Gastrointestinal tract complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996, 156:1530-1536.
20. Singh G, Triadafilopoulus G: Epidemiology of NSAID-induced GI complications. Rheumatology 1999, 26(Suppl 1):18-24.
21. Lichtenstein DR, Syngal S, Wolfe MM: Non-steroidal anti-inflammatory drugs and the gastrointestinal tract: the double-edged sword. Arthritis Rheum 1995, 38:5-18.
22. Hernandez-Diaz S, Rodriguez LAG: Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/ perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000, 160:2093-2099.
23. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al.: Risk of upper gastrointestinal ulcer bleeding associated with cyclo-oxygenase 2 inhibitors, traditional non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006, 55:1731-1738.
24. Singh G, Wang H, Mithal A, et al.: Comparing apples with oranges: choice of comparator non-selective NSAIDs alters the gastrointestinal safety advantages of COX2 inhibitors in clinical trials of arthritis patients [abstract SAT0264]. Presented at the Annual European Congress of Rheumatology, Barcelona 2007. Ann Rheum Dis 2007, 66(Suppl II):510.
25. Singh G, Triadafilopoulos G: Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID-related gastrointestinal damage. Int J Clin Pract 2005, 59:1210-1217.
26. Ibanez I, Vendrell L, Moretti U, et al.: Upper gastrointestinal bleeding associated with anti-platelet drugs. Aliment Pharmacol Ther 2006, 23:235-242.
27. Rostom A, Dube C, Wells G, et al.: Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002, 4:CD002296.
28. Chan FK, Chung SC, Suen BY, et al.: Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
29. Hinz B, Brune K: Cyclooxygenase2--10 years later. J Pharmacol Exp Ther 2002, 300:367-375.
30. Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med 2004, 351:1709-1711.
31. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520-1528.
32. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1081-1091
33. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1090.
34. FDA statement on stopping Celebrex trial. December 17, 2004. Available at http://www.fda.gov.bbs/topics/news/2004/NEW01144.html. Accessed July 2007.
35. EMEA press release on non-selective NSAIDs. August 2, 2005. Available at http://www.emea.eu.int/pdfs/human/press/pr/2473230Sen.pdf. Accessed July 2007.